Alzamend Neuro files amended Series B preferred stock designation and eliminates Series A

Alzamend Neuro, Inc.

Filed amended and restated certificate of designations for Series B preferred stock on March 1, 2024.
Amendment corrects references from Series A to Series B and clarifies voting rights per Nasdaq rules.
Filed certificate of elimination to remove Series A convertible preferred stock from charter, effective March 1, 2024.
No changes to preferences and rights of Series B beyond the correction and clarification.
All actions are procedural with no financial or operational impact disclosed.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Alzamend Neuro, Inc.: Filed Certificate of Elimination for Series A Convertible Preferred Stock, removing its designation from the Certificate of Incorporation (effective 2024-03-01).

Change: charter amendment
Effective: 2024-03-01

Exact text from the filing

on March 1, 2024, the Company filed with the Secretary of State of the state of Delaware, a Certificate of Elimination of the Certificate of Designations of Preferred Stock of Alzamend Neuro, Inc. (the “ Certificate of Elimination ”), with respect to the Company’s Series A convertible preferred stock, par value $0.0001 per share (“ Series A Convertible Preferred Stock ”).

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Alzamend Neuro, Inc.: Filed Amended and Restated Certificate of Designations for Series B Preferred Stock to correct references and clarify voting rights (effective 2024-03-01).

Change: charter amendment
Effective: 2024-03-01

Exact text from the filing

On March 1, 2024, the Company filed with the Secretary of State of the state of Delaware an Amended and Restated Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the “ Amended and Restated Certificate of Designations ”).

View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

Alzamend Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001214659-24-004200

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.